表纸
市场调查报告书

类淀粉蛋白沉积症:开发中产品分析

Amyloidosis - Pipeline Review, H1 2019

出版商 Global Markets Direct 商品编码 192465
出版日期 内容资讯 英文 199 Pages
订单完成后即时交付
价格
Back to Top
类淀粉蛋白沉积症:开发中产品分析 Amyloidosis - Pipeline Review, H1 2019
出版日期: 2019年02月01日内容资讯: 英文 199 Pages
简介

以类淀粉蛋白沉积症知名的疾病群,是由于Amyloid蛋白质在体内组织异常积蓄所造成。由于会影响到内脏形状及功能,甚至也可能最后造成脏器功能衰竭。因素有被称为L锁的异常蛋白质错误折叠,持续下去后积蓄于体内。也可能是透析结果造成。其常见的症状有倦怠感、胸痛、肿胀、呼吸障碍等。治疗方法包含有移植、给药(利尿剂、化疗药)等。

本报告提供类淀粉蛋白沉积症的治疗药开发情形调查分析,提供您开发中产品概要,临床实验的各阶段产品概要,主要企业简介,药物简介,开发中产品的最新趋势等相关的系统性资讯。

目录

简介

类淀粉蛋白沉积症概要

治疗药的开发

  • 开发中产品:概要
  • 开发中产品:比较分析

开发中的治疗药:各企业

调查中的治疗药:大学/研究机关别

开发中产品的概要

  • 后期阶段的产品
  • 临床实验阶段的产品
  • 初期阶段的产品

开发中的产品:各企业

调查中的产品:大学/研究机关别

开发治疗药的企业

  • Alnylam Pharmaceuticals, Inc.
  • Arcturus Therapeutics, Inc
  • Bellus Health Inc.
  • Bsim2
  • Celgene Corporation
  • GlaxoSmithKline Plc
  • Isis Pharmaceuticals, Inc.
  • Millennium Pharmaceuticals, Inc.
  • Onyx Pharmaceuticals, Inc.
  • Pfizer Inc.
  • ProteoTech, Inc.
  • Prothena Corporation Plc
  • SOM Innovation Biotech SL

治疗药的评估

  • 单独疗法的情况
  • 联合治疗的情况
  • 标的别
  • 各作用机制
  • 各给药途径
  • 各分子类型

药物简介

  • ALN-TTRsc02
  • Antisense RNAi Oligonucleotides to Inhibit Amyloid Precursor Protein for Amyloidosis
  • carfilzomib
  • CLR-01
  • eprodisate disodium
  • GSK-2315698 + GSK-2398852
  • GSK-2398852
  • ixazomib citrate
  • LUNAR-101
  • LUNAR-102
  • Monoclonal Antibody for Amyloidosis
  • Monoclonal Antibody to Inhibit ATTR for Familial Amyloid Polyneuropathy
  • NEOD-001
  • NPT-005
  • patisiran
  • pomalidomide
  • PTI-110
  • revusiran
  • Small Molecules for AL Amyloidosis
  • Small Molecules to Inhibit Transthyretin for Familial Amyloid Polyneuropathy
  • Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Cardiomyopathy
  • Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Polyneuropathy
  • tafamidis meglumine
  • tolcapone

开发中产品的最新趋势

暂停的计划

开发中止的产品

产品开发的里程碑

  • 最新消息和新闻稿

附录

图表

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GMDHC11092IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Amyloidosis - Pipeline Review, H1 2019, provides an overview of the Amyloidosis (Metabolic Disorders) pipeline landscape.

Abnormal accumulation of amyloid protein in the tissues results in a group of diseases known as amyloidosis. It may affect the shape and functioning of the organ eventually leading to organ failure. Predisposing factors are misfolding of abnormal protein called the light chain and its subsequent deposition in the body. It may also occur as a result of dialysis. Symptoms include fatigue, chest pain, swelling and breathing problems. Amyloidosis can be managed by transplant and, medication such as diuretics and chemotherapy drugs.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Amyloidosis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Amyloidosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Amyloidosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Amyloidosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 3, 8, 5, 6 and 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 1 and 1 molecules, respectively.

Amyloidosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Amyloidosis (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Amyloidosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Amyloidosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Amyloidosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Amyloidosis (Metabolic Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Amyloidosis (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Amyloidosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Amyloidosis - Overview
  • Amyloidosis - Therapeutics Development
  • Amyloidosis - Therapeutics Assessment
  • Amyloidosis - Companies Involved in Therapeutics Development
  • Amyloidosis - Drug Profiles
  • Amyloidosis - Dormant Projects
  • Amyloidosis - Discontinued Products
  • Amyloidosis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Amyloidosis, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Products under Development by Companies, H1 2019 (Contd..2), H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Amyloidosis - Pipeline by Akcea Therapeutics Inc, H1 2019
  • Amyloidosis - Pipeline by Alnylam Pharmaceuticals Inc, H1 2019
  • Amyloidosis - Pipeline by Amgen Inc, H1 2019
  • Amyloidosis - Pipeline by Bsim2, H1 2019
  • Amyloidosis - Pipeline by Celgene Corp, H1 2019
  • Amyloidosis - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2019
  • Amyloidosis - Pipeline by Eidos Therapeutics Inc, H1 2019
  • Amyloidosis - Pipeline by Johnson & Johnson, H1 2019
  • Amyloidosis - Pipeline by Neurimmune Holding AG, H1 2019
  • Amyloidosis - Pipeline by Oncopeptides AB, H1 2019
  • Amyloidosis - Pipeline by Pfizer Inc, H1 2019
  • Amyloidosis - Pipeline by Prothena Corp Plc, H1 2019
  • Amyloidosis - Pipeline by R Pharm, H1 2019
  • Amyloidosis - Pipeline by Regeneron Pharmaceuticals Inc, H1 2019
  • Amyloidosis - Pipeline by Spectrum Pharmaceuticals Inc, H1 2019
  • Amyloidosis - Dormant Projects, H1 2019
  • Amyloidosis - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Amyloidosis, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Top 10 Targets, H1 2019
  • Number of Products by Stage and Top 10 Targets, H1 2019
  • Number of Products by Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Top 10 Molecule Types, H1 2019
  • Number of Products by Stage and Top 10 Molecule Types, H1 2019
Back to Top